Thinking big, Bayer’s Axel Bouchon tackles stem cell field with $225M startup partnered with Versant
Bayer’s Axel Bouchon has struck again.
Less than four months since the Bayer exec struck a deal with CRISPR Therapeutics to launch a gene editing JV named Casebia, he’s back with a new collaboration, this time focused on stem cells.
This time Bayer and Bouchon are teaming up with Versant Ventures to finance a new company called BlueRock, handing over $225 million in financing to pursue new regenerative medicines for heart disease and Parkinson’s, according to the Wall Street Journal, which was handed the exclusive ahead of a formal announcement early next week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.